Edwards Lifesciences
This article was originally published in The Gray Sheet
Executive Summary
Baxter cardiovascular device business spin-off is now expected to be finalized before April (1"The Gray Sheet" Jan. 10, p. 8). Edwards will take with it $550 mil. in debt from Baxter